A prospective matched case-control study on the genomic epidemiology of colistin-resistant Enterobacterales from Dutch patients

Abstract Background Colistin is a last-resort treatment option for infections with multidrug-resistant Gram-negative bacteria. However, colistin resistance is increasing. Methods A six-month prospective matched case-control study was performed in which 22 Dutch laboratories with 32 associated hospitals participated. Laboratories were invited to send a maximum of five colistin-resistant Escherichia coli or Klebsiella pneumoniae (COLR-EK) isolates and five colistin-susceptible isolates (COLS-EK) to the reference laboratory, matched for patient location, material of origin and bacterial species.... Mehr ...

Verfasser: Vendrik, Karuna E. W.
de Haan, Angela
Witteveen, Sandra
Hendrickx, Antoni P. A.
Landman, Fabian
Notermans, Daan W.
Bijkerk, Paul
Schoffelen, Annelot F.
de Greeff, Sabine C.
Wielders, Cornelia C. H.
Goeman, Jelle J.
Kuijper, Ed J.
Schouls, Leo. M.
Heemstra, Karen
Vainio, Saara
Ott, Alewijn
de Jager, Steve
Koene, Fleur
Hira, Vishal
van Burgel, Nathalie
Muller, Anouk
Nagtegaal-Baerveldt, Karolien
van der Meer, Coby
van den Biggelaar, Rik
Pontesilli, Oscar
van Mens, Suzan
van den Bijllaardt, Wouter
Kolwijck, Eva
Bosboom, Ron
Frénay, Ine
van ’t Veen, Annemarie
Troelstra, Annet
Kampinga, Greetje
van Dijk, Karin
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Reihe/Periodikum: Communications Medicine ; volume 2, issue 1 ; ISSN 2730-664X
Verlag/Hrsg.: Springer Science and Business Media LLC
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29044330
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.1038/s43856-022-00115-6

Abstract Background Colistin is a last-resort treatment option for infections with multidrug-resistant Gram-negative bacteria. However, colistin resistance is increasing. Methods A six-month prospective matched case-control study was performed in which 22 Dutch laboratories with 32 associated hospitals participated. Laboratories were invited to send a maximum of five colistin-resistant Escherichia coli or Klebsiella pneumoniae (COLR-EK) isolates and five colistin-susceptible isolates (COLS-EK) to the reference laboratory, matched for patient location, material of origin and bacterial species. Epidemiological/clinical data were collected and included in the analysis. Characteristics of COLR-EK/COLS-EK isolates were compared using logistic regression with correction for variables used for matching. Forty-six ColR-EK/ColS-EK pairs were analysed by next-generation sequencing (NGS) for whole-genome multi-locus sequence typing and identification of resistance genes, including mcr genes. To identify chromosomal mutations potentially leading to colistin resistance, NGS reads were mapped against gene sequences of pmrAB, phoPQ, mgrB and crrB . Results In total, 72 COLR-EK/COLS-EK pairs (75% E. coli and 25% K. pneumoniae ) were included. Twenty-one percent of COLR-EK patients had received colistin, in contrast to 3% of COLS-EK patients (OR > 2.9). Of COLR-EK isolates, five contained mcr-1 and two mcr-9 . One isolate lost mcr-9 after repeated sub-culturing, but retained colistin resistance. Among 46 sequenced COLR-EK isolates, genetic diversity was large and 19 (41.3%) isolates had chromosomal mutations potentially associated with colistin resistance. Conclusions Colistin resistance is present but uncommon in the Netherlands and caused by the mcr gene in a minority of COLR-EK isolates. There is a need for surveillance of colistin resistance using appropriate susceptibility testing methods.